Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDA-TIL in Multiple Tumor Types
NCT03610490Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2018
- Primary completion
- Aug 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MDA-TIL in ovarian cancer, colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2018; status: terminated.
02
Drugs
MDA-TIL
03
Conditions
ovarian cancercolorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03610490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610490.